Passthrough and BlackRock's Aladdin® Collaborate to Enhance Investor Experience on the eFront Platform
NEW YORK--(BUSINESS WIRE)--Passthrough, a leader in fund workflow automation, and Aladdin ®, BlackRock's technology business, today announced a partnership that integrates Passthrough's digital subscription technology within the eFront platform to offer a unified investor experience. The collaboration enables common clients – from general partners to asset servicers – to digitize their investor onboarding process and deliver scalable investor relations solutions for their clients.
'BlackRock continues to set new standards for how institutional investors participate in the private markets ecosystem at large,' said Tim Flannery, Co-founder and CEO of Passthrough. 'With this integration, together, we're removing friction from the moment investors log in - giving them one clear, intuitive path from interest to investment.'
Now live, the integration enables eFront users to streamline and automate onboarding and fund closings for their investors. Using Passthrough's technology, it's now easier to distribute and execute subscription documents electronically, accelerating subscription workflow and reporting. Over time, the two companies will collaborate further to embed Passthrough's full onboarding flow – including subscription agreements, tax forms, and AML requests – within eFront's investor experience.
"This is an additional proof point in our journey to make private markets more accessible and transparent through data and technology. Our collaboration with Passthrough enhances our private markets technology capabilities for the benefit of our common eFront clients - including BlackRock - by optimizing the investor experience through the investment lifecycle,' said Kamya Somasundaram, Managing Director, Global Head of Aladdin Partnerships.
Through this partnership, BlackRock will also leverage Passthrough's technology to streamline onboarding for clients in its private markets business.
About Passthrough
Passthrough automates investor onboarding and compliance workflows for private funds. From subscription documents and tax forms to AML and KYC processes, Passthrough eliminates friction for both investors and fund managers. The platform connects directly to CRMs, investor portals, and fund admin systems to provide a seamless, API-first experience across the investor lifecycle. Learn more at passthrough.com.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
4 hours ago
- Yahoo
BlackRock sets $400bn fundraising goal for private investment growth
BlackRock has placed a significant focus on expanding its private investment businesses, with plans to nearly double its market value by 2030, reported Financial Times (FT). The New York-based firm has set a fundraising goal of approximately $400bn for its private investment divisions, reflecting a strategic shift to compete with other alternative asset giants. The company's 2030 vision was outlined as it seeks to challenge competitors such as Blackstone, Apollo Global Management, and KKR in the alternative asset space. BlackRock's acquisitions, including a $28bn investment to purchase Global Infrastructure Partners, HPS Investment Partners, and the latest acquisition of Preqin, demonstrate a pivot from its public market origins towards private markets. Under BlackRock's stewardship, GIP has already made a significant move by acquiring a portfolio of ports valued at $22.8bn, including strategic assets by the Panama Canal. Additionally, a collaboration with Microsoft has been established to create a new $30bn artificial intelligence investment fund. The acquisition of HPS is expected to be finalised in July. BlackRock CEO Larry Fink, who is set to address investors, has emphasised the growing client demand for private market investments. With an anticipated annual revenue growth of around 10%, BlackRock projects that its yearly income could surpass $35bn by 2030. The firm anticipates that private investment and technology businesses will contribute over 30% of its revenue by 2030, a significant increase from 15% at the end of last year. This translates to a yearly fundraising goal of about $65bn from 2025 to 2030 for the private investment sectors. Furthermore, BlackRock has established a $15bn adjusted operating income target and envisions its market value escalating to $280bn by 2030, a substantial rise from its current $154bn valuation. "BlackRock sets $400bn fundraising goal for private investment growth" was originally created and published by Private Banker International, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
Yahoo
4 hours ago
- Yahoo
Debiopharm's ADC Research Gains Momentum With Launch of First-in-human Trial Assessing Debio 1562M in Acute Myeloid Leukemia Patients
First patient dosed with Debiopharm's first-in-class CD37 targeted antibody drug conjugate (ADC) in a Phase 1/2, multicenter, open-label trial, for patients with acute myeloid leukemia (AML) LAUSANNE, Switzerland, June 16, 2025--(BUSINESS WIRE)--Debiopharm ( a privately-owned, Swiss-based biopharmaceutical company aiming to establish tomorrow's standards of care to cure cancer and infectious diseases, today announced that the first patient has been dosed in the first-in-human clinical trial evaluating the safety, tolerability, and antileukemic activity of Debio 1562M monotherapy in patients with relapsed/refractory (R/R) acute myeloid leukemia (AML). This phase 1/2 trial (NCT06969430) will lay the groundwork for further development as it will allow the characterization of the safety and tolerability of the drug, dose optimization, and define the product's activity. AML remains a significant unmet need in oncology, particularly for older adults who account for the majority of cases. Despite advances in our understanding of AML biology and the introduction of new therapies, outcomes remain dismal for many patients—especially those who are not candidates for intensive treatments such as traditional chemotherapy or stem cell transplantation. While intensive chemotherapy and targeted therapies are available, they have not substantially improved long-term outcomes across all patient populations. The 5-year overall survival (OS) rate remains at just 32%1, with a median OS as low as 7 months in certain populations.2 This stark therapeutic gap leaves thousands of patients without viable treatment options each year, highlighting an urgent need for innovative interventions capable of extending survival. Transformative solutions are critical to improving both prognosis and quality of life for this underserved population within the AML treatment landscape. "It's time for AML research to advance with more precise therapeutic options," expressed Marianna Muller, Senior Medical Director, Oncology, Debiopharm. "This study will help us better understand the potential of Debio 1562M and how it could provide an effective new treatment while minimizing tolerability challenges for patients facing this very difficult disease with high unmet medical need." CD37, a cell-surface antigen, has been shown to be a relevant ADC target in AML due to its broad expression on blasts and leukemic stem cells along with efficient internalization.3 Research reveals that this increased expression is restricted to malignant cells compared to healthy hematopoietic stem cells and is correlated with poor patient outcomes.3 Debio 1562M is a next generation ADC targeting CD37 with 1st-in-class potential. The compound was designed using Debiopharm's Trifecta approach optimizing 3 key components: naratuximab - an anti-CD37 monoclonal antibody, Multilink™ proprietary linker technology, and a microtubule inhibitor as cytotoxic payload. In pre-clinical studies, Debio 1562M showed anti-leukemic activity across all AML subtypes as well as superior activity vs. the current standard-of-care and targeted therapies in AML models. Debiopharm has been involved in targeted drug delivery for more than a decade, developing MultiLink™—our unique and versatile proprietary ADC technology suite, key components of which are integrated into this product. We recognize how critical the need is for AML patients and remain dedicated to addressing it through our ADC expertise. As our pre-clinical results have shown promising antitumor activity and tolerability in this hard-to-treat leukemia, we're looking forward to seeing what this clinical stage research with Debio 1562M could reveal," mentioned Bertrand Ducrey, CEO of Debiopharm. Debiopharm's ADC Expertise We're developing fit-for-purpose antibody-drug conjugates (ADCs) through a tailored "Trifecta" approach: strategic target selection, innovative MultiLink™ linker technology, and smart payload choices. Our ADC portfolio includes first-in-class or best-in-class candidates: Debio 1562M, a CD37-targeted ADC for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS), and Debio 0532, an HER3-targeted ADC for solid tumors, as well as other undisclosed targets. We are actively partnering to access innovative targets, co-develop, or out-license our ADC programs. Key partnerships include options to in-license bispecific antibodies targeting HER2-HER3 and HER3-EGFR. To enable both high drug-to-antibody ratios (DAR) and high stability, our ADCs are designed with our proprietary MultiLink™ linker technology. We have strong in-house capabilities and in-depth expertise spanning ADC conjugation and optimization, pharmacokinetics/pharmacodynamics (PK/PD), toxicology, translational, pharmaceutical (CMC) and clinical development, and supply chain management. We continue to invest in and explore potential game-changing technologies, such as novel and dual payloads. Debiopharm's Commitment to Patients Debiopharm aims to develop innovative therapies that target high unmet medical needs in oncology and bacterial infections. Bridging the gap between disruptive discovery products and real-world patient reach, we identify high-potential compounds and technologies for in-licensing, clinically demonstrate their safety and efficacy, and then hand stewardship to large pharmaceutical commercialization partners to maximize patient access globally. For more information, please visit Follow us on LinkedIn @DebiopharmInternational Sources [1] National Cancer Institute. 2020. SEER Cancer Stat Facts: Acute Myeloid Leukemia. Available at: [2] Meyers J, et al. Applied health economics and health policy. 2013 11 (3): 275-286. [3] Lisa Ivanschitz, AACR 2025 Abstract # 1160 View source version on Contacts Debiopharm Contact Dawn BonineHead of Tel: +41 (0)21 321 01 11 Sign in to access your portfolio
Yahoo
6 hours ago
- Yahoo
BlackRock's Virtual Investment Analyst ‘Asimov' Ushers in AI Era on Wall Street
'Hey AI, maximize my portfolio returns,' is a prompt that has moved from speculative fiction to Wall Street. Last week, BlackRock, the world's largest asset manager, unveiled an AI research platform called 'Asimov' at the company's investor day in New York. Chief Operating Officer Rob Goldstein described the research platform as a 'virtual investment analyst' that can scan text in research notes, regulatory filings and emails to produce 'portfolio insights.' READ ALSO: Act of GENIUS or Blockheaded Bill? Congress Considers Stablecoins and Can Blue Origin Fill NASA's SpaceX Void? BlackRock isn't the first, nor will it be the last, asset manager to pick up AI tools as Wall Street firms jockey for a competitive edge. Systematic hedge fund manager Man Group AHL, which has been using machine learning techniques for over a decade, described how the firm was using it to be more productive in a July 2024 report. Man AHL was developing chatbots that could understand the firm's internally developed code. It involved testing processes in which ChatGPT scanned 200-page offering circulars for catastrophe bonds and input relevant information into a template that another person would review. ChatGPT could also answer investor queries, extracting relevant information from company documents including fact sheets, presentations, and investment commentaries. AI might also analyze macroeconomic data at the level of a junior quantitative analyst. Others have deployed AI for portfolio construction: Bridgewater Associates CEO Nir Bar Dea stated at a Bloomberg Invest conference earlier this year that a fund launched in 2024, which utilizes machine learning to make decisions, delivered performance comparable to its human-led counterparts. Researchers at Stanford Graduate School of Business built an AI analyst that bested humans, beating 93% of human fund managers over 30 years by an average of 600%. The bot was fed portfolio data from about 3,300 actively managed US stock mutual funds between 1990 and 2020 and nosed out alpha by tweaking fund holdings once every quarter. *AI Alpha: The academic exercise showed that, in hindsight, publicly available information wasn't fully exploited. Though Stanford's AI analyst was able to shoot the lights out in hindsight, it wouldn't necessarily outperform in today's market. And here's the rub: 'If every investor were using this tool, then much of the advantage would go away,' Suzie Noh, assistant professor of accounting, said in an interview with the university. This post first appeared on The Daily Upside. To receive delivering razor sharp analysis and perspective on all things finance, economics, and markets, subscribe to our free The Daily Upside newsletter. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
